Fibroids treated with MR-HIFU

Virtually all types of fibroid can be treated, provided they can be reached by the HIFU beam without the beam's path being blocked by the intestine. Subserosal, intramural and submucosal fibroids can be subjected to routine treatment. Subserosal fibroids can be treated up to a margin of 1.5 cm from the serosal surface. In women who do not wish to have children, submucosal fibroids can be treated up to the endometrial surface. Pedunculated fibroids with thin stalks must not be treated.

As MR imaging is used to plan the treatment, MR characteristics are used to determine which fibroids respond best to HIFU treatment. Fibroids with low signal intensity in pretherapeutic T2-weighted images (dark fibroids) shrink more than fibroids with high signal intensity (light fibroids).


Due to the heterogeneous nature of the fibroid tissue and patient-specific, physiological differences in the near field, it is anticipated that, when using methods to determine the fibroid type prior to MR-HIFU therapy, other factors, such as DCE-MR, will also need to be considered. A combination of anatomical findings and the MR image characteristics must therefore be used to determine whether MR-HIFU is the best treatment for a particular patient.

There may be some practical considerations that prevent a patient from having MR-HIFU therapy. Certain patient characteristics can cause difficulties when treating fibroids located deep within the body with MR-HIFU. The geometric focus of the transducer is 14 cm from the transducer surface. The distance between the skin and the center of the fibroid must be approximately 10 cm in order to ensure treatment is as easy as possible. If a patient has a very thick layer of subcutaneous fatty tissue or the fibroid is located too far back, more careful preparation may be needed to ensure that the treatment reaches the entire fibroid.

Care must also be taken with any large scars from previous pelvic operations if the scars are located in the path of the ultrasonic beam. Ultrasonic energy must not be directed through fresh and/or extensive scars as it may cause localized heating of the tissue. These structures can be avoided by positioning the patient in such a way as to change the path of the beam. The beam-shaping feature of the MR-HIFU software can be used for this purpose or a protective cover can be placed over the scar tissue. Finally, all contraindications that apply to MRI scans (e.g. pacemakers etc.) are also applicable to MR-HIFU therapy.

There is currently no restriction on the percentage of a fibroid that can be treated with MR-HIFU, however a treatment volume of at least 50–60% of the total fibroid volume is currently recommended. Physicians currently aim to relieve the patient's most acute symptoms. This may mean that one fibroid is treated, but others are not, and/or that the total treatment volume is reduced.


This site is solely intended for residents of Germany where the SONALLEVE® MR-HIFU has been granted CE Marking and is authorized for sale by applicable health regulatory authorities. This site contains information about treatment options that are not available in every country. Each country has specific laws, regulations, and medical practices governing the communication of information about medical treatments. Nothing on this site should be construed as a solicitation or promotion for any treatment which is not authorized by the laws and regulations of the country where the reader resides. At this time, SONALLEVE is not approved for commercial sale in the USA and does not have FDA clearance. The content of this site is provided for informational purposes only. This site does not provide medical advice nor does it provide instruction on the appropriate use of products. The information on this site is not intended to, and should not, replace or substitute the advice of your physician or other qualified healthcare professional. Absolutely no information contained or accessible through this site should be construed as taking the place of your physician’s advice. You should always discuss any health-related questions with your own physician and other healthcare professionals involved in your treatment and care. Profound Medical is not responsible for any reliance or decisions made by you based on the information available on this site. Do not use this information to diagnose or treat a medical condition or health problem. You should never disregard or delay seeking medical advice because of something that you have seen on this site. Every medical treatment has risks and benefits and no outcome can ever be guaranteed. By accessing or using this site (including all content and functionality), you agree to be bound by the Terms of Use and you also agree to the terms in our Privacy Policy, which explains what information we collect, how we gather and use the information, our policies for protecting and disclosing information, and the options you have regarding your information. If you do not agree with any the Terms of Use or our Privacy Policy, please do not access or use the site.